Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to $40.9 million.

  • IDEAYA Biosciences' Accumulated Expenses rose 3472.59% to $40.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $40.9 million, marking a year-over-year increase of 3472.59%. This contributed to the annual value of $40.9 million for FY2025, which is 3472.59% up from last year.
  • As of Q4 2025, IDEAYA Biosciences' Accumulated Expenses stood at $40.9 million, which was up 3472.59% from $45.3 million recorded in Q3 2025.
  • IDEAYA Biosciences' 5-year Accumulated Expenses high stood at $45.3 million for Q3 2025, and its period low was $7.8 million during Q1 2021.
  • Its 5-year average for Accumulated Expenses is $21.4 million, with a median of $17.1 million in 2022.
  • As far as peak fluctuations go, IDEAYA Biosciences' Accumulated Expenses surged by 8973.77% in 2021, and later crashed by 948.86% in 2023.
  • IDEAYA Biosciences' Accumulated Expenses (Quarter) stood at $12.3 million in 2021, then skyrocketed by 37.98% to $17.0 million in 2022, then rose by 10.34% to $18.8 million in 2023, then soared by 61.83% to $30.4 million in 2024, then soared by 34.73% to $40.9 million in 2025.
  • Its last three reported values are $40.9 million in Q4 2025, $45.3 million for Q3 2025, and $37.8 million during Q2 2025.